SS-A (Ro) antibody in random mother-infant pairs

MICHAEL CALMES, BRUCE A BARTHOLOMEW

From the Texas Tech University Health Sciences Center, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Lubbock, Texas

SUMMARY  In a study of the occurrence of detectable antibodies to SS-A and SS-B in 300 randomly selected mother-infant pairs, three (1%) mother-infant pairs were positive for precipitating antibodies to SS-A. No matched pairs were positive for SS-B. Review of the clinical history of the mother-infant pairs with SS-A antibodies failed to reveal evidence of connective tissue disease or the neonatal lupus syndrome. Follow up of two of the three SS-A positive mother-infant pairs two months after delivery also showed no evidence of disease. While the SS-A antibody may be closely associated with the development of the neonatal lupus syndrome, our study does not support the proposed aetiological nature of the antibody. Random maternal screening for possible SS-A antibody positivity and potential neonatal lupus syndrome does not appear to be warranted.

Neonatal lupus syndrome occurs in infants within the first few months of life and is a transient phenomena. The most common clinical manifestations are erythema annulare centrifugum and congenital heart block. Other associated manifestations include lymphadenopathy, hepatosplenomegaly, and haematological abnormalities consisting of leucopenia, haemolytic anaemia, or thrombocytopenia.

The aetiology of the syndrome is unknown. It occurs in infants of mothers with symptomatic connective tissue disease and in infants of asymptomatic mothers with or without connective tissue disease. The SS-A (Ro) antibody has been found in infants with the neonatal lupus syndrome and it has been suggested that transplacental transfer of this antibody is a possible cause.

This study was undertaken to determine the incidence of detectable concentrations of SS-A antibodies in normal mothers and their newborn infants and the predictive value of this measurement for the development of the neonatal lupus syndrome.

Patients and methods

Blood samples were obtained by venepuncture from 300 randomly selected mothers in active labour admitted to labour and delivery during September and October 1983 and from the cords of their respective infants at the time of delivery. The patient population divided by ethnic group was as follows: 50% Mexican-American, 35% white, and 15% black. The serum was withdrawn and stored at −40°C until assay.

Serum samples were tested for the presence of precipitating antibodies to SS-A and SS-B antigens using double immunodiffusion techniques. The source of antigens was calf thymic extract supplied by Alpha Antigens Inc. Serum samples with precipitating antibodies were compared with reference samples known to contain precipitating antibodies to either SS-A or SS-B antigens as controls. Antinuclear antibody testing using the immunofluorescent technique on human epithelial cells (HEp-2 cells) was performed on the samples from mother-infant pairs who were positive for SS-A antibodies.

Results

Four maternal (1.3%) and four cord (1.3%) samples contained the SS-A antibody. Of these, three maternal and three infant samples belonged to matched mother-infant pairs. The other two positive sera were from one mother with an infant negative for SS-A antibodies and from one infant with a negative mother.

On review of hospital records of the isolated, unmatched positive pairs no evidence of manifestations of connective tissue disease or neonatal lupus syndrome was found in mother and infant respectively. Follow up on these patients was not available. The three SS-A positive mothers, who each delivered one infant also positive for SS-A anti-
bodies, had no evidence of a history or current manifestations of connective tissue disease and no evidence of current infection. Likewise, each of their respective infants had no evidence of neonatal lupus syndrome during their stay in hospital in the immediate postpartum period.

Two of the three SS-A antibody positive mother-infant pairs were available for follow up about two and a half months after birth. Neither mother presented with any evidence of connective tissue disease and neither infant presented with any manifestation of the neonatal lupus syndrome. Both infants had normal electrocardiograms without evidence of any heart block (Table 1).

Antinuclear antibody testing performed on all SS-A antibody positive mother-infant pairs showed one pair with both negative, one pair in which the mother was negative and the infant was antinuclear antibody positive (1/40 homogeneous) and one pair in which both were antinuclear antibody positive (1/40 homogeneous).

Of the 300 maternal samples tested, only one was positive for SS-B antibodies. There were no SS-B antibody positive infants in the 300 infant samples tested.

**Discussion**

Neonatal lupus syndrome usually develops between birth and three months of age. Usually, the presentation is characterised by cutaneous lesions of erythema annularis, which often manifests as a photosensitive reaction. Erythematous cutaneous lesions in infants have been reported to be associated with a maternal autoimmune disease since 1954.1 Hammer7 reported three infants with erythema annulare centrifugum whose mothers all had documented or suspected diagnoses of systemic lupus erythematosus. Several studies since have documented the frequent association of SS-A antibodies in mothers whose infants developed the neonatal lupus syndrome.8-10 Most of these studies have suggested transplacental passage of the IgG antibodies as a possible cause.

Congenital heart block may occur in conjunction with other manifestations of the neonatal lupus syndrome or as an isolated finding.8-13 Similarly, studies have linked the association of the SS-A antibody to congenital heart block in infants with the syndrome.13 SS-A antibody has recently been detected in 83% of mothers of infants with isolated congenital heart block.13 In the same study, the antibody was present in seven of eight infants with isolated congenital heart block when their serum was tested before three months of age.

A previous study of 50 normal mother-infant pairs found no positive individuals for the SS-A antibody.13 Weston et al11 likewise studied 71 infants from birth to five months of age, of whom 45 were healthy and the others had various reactive erythemas. All 71 of their subjects were negative for SS-A and SS-B antibodies (Table 2).

In our study 300 randomly selected mother-infant pairs were tested for SS-A and SS-B antibodies. Three (1%) of the 300 mother-infant pairs were positive for SS-A antibody but we found no evidence of autoimmune disease or neonatal lupus syndrome in the mothers or infants respectively at the time of birth. Further, no disease activity was ascertained in the two mother-infant pairs available for follow up two and a half months after birth.

The presence of antibody in pairs may represent some antibody cross reactivity with the SS-A antigen, which is also transplacentally passed to the infant. If, however, in fact represents true SS-A antibody positivity, which may occur in mothers who are asymptomatic for connective tissue disease, then one must either question the aetiological nature of the antibody in producing the neonatal lupus syndrome or assume that an additional, unknown factor determines susceptibility or expression. Some significant titre of antibody may be necessary for disease expression and further prospective analysis using data on antibody titre should be performed. The SS-A antibody may serve as a marker or be a consequence of the disease processes without being the actual cause of the disease. Of interest is the recent finding of an unusual prevalence of the SS-A

---

**Table 1**  
**SS-A antibody positive mother-infant pairs**

<table>
<thead>
<tr>
<th>Pair</th>
<th>SS-A</th>
<th>SS-B</th>
<th>ANA</th>
<th>History of clinical disease at birth</th>
<th>History of clinical disease at follow up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mother</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>Negative</td>
<td>Negative</td>
</tr>
<tr>
<td>Infant</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>Negative</td>
<td>Negative</td>
</tr>
<tr>
<td>Mother</td>
<td>+</td>
<td>-</td>
<td>+ (1/40)</td>
<td>Negative</td>
<td>Negative</td>
</tr>
<tr>
<td>Infant</td>
<td>+</td>
<td>-</td>
<td>+ (1/40)</td>
<td>Negative</td>
<td>Not available</td>
</tr>
</tbody>
</table>

ANA = antinuclear antibody.
SS-A (Ro) antibody in random mother-infant pairs

Table 2  Summary of reported random control sera tested for SS-A and SS-B antibodies

<table>
<thead>
<tr>
<th></th>
<th>Positive for</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SS-A</td>
</tr>
<tr>
<td>Weston et al11</td>
<td>71 infants</td>
</tr>
<tr>
<td>Scott et al13</td>
<td>50 mothers*</td>
</tr>
<tr>
<td>Present study</td>
<td>300 mothers*</td>
</tr>
</tbody>
</table>

*Matched mother-infant pairs

(Ro) antibody in homozygous C2 deficiency associated with systemic lupus erythematosus like illness.15 Previous reports of neonatal lupus syndrome have not included data on complement component levels. From the studies available, the data do not appear to confirm nor disprove the proposed aetiological link between the presence of SS-A antibodies and the neonatal lupus syndrome.

Certainly, more studies are needed to evaluate the efficacy of random maternal screening for the presence of SS-A antibodies. Perhaps measurements of simultaneous serum complement components, especially C2, would be useful in patients positive for the SS-A antibody. Our study suggests that any predictive nature of SS-A antibody is doubtful, and SS-A antibody testing would appear not to be cost effective as a mass screening procedure in the detection of infants with the potential to develop neonatal lupus syndrome.

References


Requests for reprints to: Dr Michael Calmes, Texas Tech University Health Sciences Center, School of Medicine, Lubbock, Texas 79430, USA.
SS-A (Ro) antibody in random mother-infant pairs.

M Calmes and B A Bartholomew

*J Clin Pathol* 1985 38: 73-75
doi: 10.1136/jcp.38.1.73

Updated information and services can be found at:
http://jcp.bmj.com/content/38/1/73

**Email alerting service**

_These include:_

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/